This app has been updated in accordance with the 2022 ACC ECDP on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk to incorporate newer nonstatin agents, such as bempedoic acid, evinacumab, and inclisiran. This update also includes improved risk discrimination in patient evaluation, now incorporating CAC scoring, evidence of subclinical atherosclerosis, and Familial Hypercholesterolemia.
Download APK on Android with Free Online APK Downloader - APKPure
Facebook
Twitter
Reddit
WhatsApp
LINE
Gmail
LinkedIn
Pinterest
Messenger
Telegram
We use cookies and other technologies on this website to enhance your user experience. By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.